5DG.F OCUMENSION THER.DL-00001

Healthcare Biotechnology Frankfurt Exchange
0.5550 EUR
Close of Nov 11, 2026
0.4300 0.9250
Market cap
EUR 443M
P/E
-
P/B
0.92x
ROE
-4.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is 5DG.F undervalued?

Graham number

The Graham number of OCUMENSION THER.DL-00001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

OCUMENSION THER.DL-00001 fundamental analysis

No fundamental analysis for OCUMENSION THER.DL-00001 yet.

OCUMENSION THER.DL-00001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About OCUMENSION THER.DL-00001

Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China. The company offers various ophthalmic drugs for the treatment of chronic non-infectious uveitis, wet age-related macular degeneration, diabetic macular edema, choroidal neovascularization, dry eye disease, glaucoma, allergic and bacterial conjunctivitis, fungus disease, and anti-inflammatory, as well as postoperativ…

Full company profile